Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escitalopram + zolpidem is a combination of two pharmaceutical drugs used together, typically in patients with major depressive disorder (MDD) who also experience insomnia. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain and is primarily indicated for depression and anxiety disorders. Zolpidem is a non-benzodiazepine hypnotic agent that acts as an agonist at the GABA-A receptor, promoting sedation and sleep. When administered concomitantly, this combination can improve insomnia symptoms and some aspects of next-day functioning in patients with MDD but does not significantly enhance antidepressant effects beyond escitalopram alone[2]. The combination may increase the risk of additive central nervous system depression, including drowsiness, somnolence, impaired judgment, dizziness, fatigue, amnesia, and other related adverse effects[1][2]. Careful monitoring or dose adjustment may be required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + zolpidem.